Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Apricus Biosc Inc (APRI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,483
  • Shares Outstanding, K 15,220
  • Annual Sales, $ 5,760 K
  • Annual Income, $ -7,430 K
  • 36-Month Beta 0.44
  • Price/Sales 4.59
  • Price/Cash Flow N/A
  • Price/Book 3.53

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.52 +13.82%
on 12/01/17
1.83 -5.46%
on 12/06/17
+0.14 (+8.81%)
since 11/13/17
3-Month
1.20 +44.17%
on 11/03/17
2.14 -19.16%
on 10/05/17
-0.05 (-2.81%)
since 09/13/17
52-Week
0.86 +101.16%
on 05/25/17
4.07 -57.49%
on 01/18/17
+0.30 (+20.98%)
since 12/13/16

Most Recent Stories

More News
SeeThruEquity Issues Update Note on Apricus Biosciences, Inc. (Nasdaq CM: MTBC) with Target Price of $4.30

NEW YORK, NY / ACCESSWIRE / November 7, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has...

APRI : 1.73 (-0.57%)
MTBC : 2.89 (-2.03%)
Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results

Vitaros U.S. NDA Resubmission Review Remains on Track

APRI : 1.73 (-0.57%)
Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus' third quarter 2017 financial results will...

APRI : 1.73 (-0.57%)
Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call

SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus'...

APRI : 1.73 (-0.57%)
Apricus Biosciences to Present at the 2017 BIO Investor Forum

SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard...

APRI : 1.73 (-0.57%)
Apricus Biosciences to Present at the 2017 BIO Investor Forum

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will present...

APRI : 1.73 (-0.57%)
SeeThruEquity Issues Company Update on Apricus Biosciences (NASDAQ:APRI) with Target Price of $4.30

NEW YORK, NY / ACCESSWIRE / October 3, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it...

APRI : 1.73 (-0.57%)
Raynauds Disease Pipeline Review, H2 2017 Featuring Allergan, Apricus Biosciences & Covis Pharmaceuticals - Research and Markets

The "Raynauds Disease - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

AGN : 168.71 (-1.84%)
APRI : 1.73 (-0.57%)
Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market

SAN DIEGO, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has...

APRI : 1.73 (-0.57%)
Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has entered into definitive agreements to sell securities...

APRI : 1.73 (-0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT '. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the...

See More

Key Turning Points

2nd Resistance Point 1.81
1st Resistance Point 1.78
Last Price 1.73
1st Support Level 1.70
2nd Support Level 1.65

See More

52-Week High 4.07
Fibonacci 61.8% 2.84
Fibonacci 50% 2.47
Fibonacci 38.2% 2.09
Last Price 1.73
52-Week Low 0.86

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.